Omeros
About OmerosPipelineInvestorsNews


Investor Relations Home

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

 
Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$20.28
Change (%) Stock is Down 0.51 (2.45%)
Volume466,475
Data as of 05/27/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
DateTitle  
05/22/15Omidria® Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use
- Unanimous Recommendation to Grant European Marketing Authorization for Omidria Based on Benefit/Risk Profile - SEATTLE, May 22, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the European Medicines Agency... 
 Printer Friendly Version
05/11/15Omeros Corporation Reports First Quarter 2015 Financial Results
-- Omidria Now Widely Available in the U.S. Following Commercial Launch -- SEATTLE, May 11, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the ... 
 Printer Friendly Version
05/05/15Omeros Corporation to Announce First Quarter 2015 Financial Results on May 11, 2015
SEATTLE, May 5, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its first quarter 2015 financial results for the period ended March 31, 2015, on Monday, May 11, 2015, after market close. ... 
 Printer Friendly Version
04/14/15European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721
-- Patients with Thrombotic Microangiopathy Will Now Be Able to Receive Extended Treatment - SEATTLE, April 14, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the presiding European regulatory authority has approved the company's investigational product OMS721 for compassionate use. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies ... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation 2014 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.